» Articles » PMID: 32184727

Nordihydroguaiaretic Acid: From Herbal Medicine to Clinical Development for Cancer and Chronic Diseases

Overview
Journal Front Pharmacol
Date 2020 Mar 19
PMID 32184727
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Nordihydroguaiaretic acid (NDGA) is a phenolic lignan obtained from , the creosote bush found in Mexico and USA deserts, that has been used in traditional medicine for the treatment of numerous diseases such as cancer, renal, cardiovascular, immunological, and neurological disorders, and even aging. NDGA presents two catechol rings that confer a very potent antioxidant activity by scavenging oxygen free radicals and this may explain part of its therapeutic action. Additional effects include inhibition of lipoxygenases (LOXs) and activation of signaling pathways that impinge on the transcription factor Nuclear Factor Erythroid 2-related Factor (NRF2). On the other hand, the oxidation of the catechols to the corresponding quinones my elicit alterations in proteins and DNA that raise safety concerns. This review describes the current knowledge on NDGA, its targets and side effects, and its synthetic analogs as promising therapeutic agents, highlighting their mechanism of action and clinical projection towards therapy of neurodegenerative, liver, and kidney disease, as well as cancer.

Citing Articles

Synergistic involvement of the NZF domains of the LUBAC accessory subunits HOIL-1L and SHARPIN in the regulation of LUBAC function.

Toda Y, Fujita H, Mino K, Koyama T, Matsuoka S, Kaizuka T Cell Death Dis. 2024; 15(11):813.

PMID: 39528476 PMC: 11555115. DOI: 10.1038/s41419-024-07199-z.


Impact of Nordihydroguaiaretic Acid on Proliferation, Energy Metabolism, and Chemosensitization in Non-Small-Cell Lung Cancer (NSCLC) Cell Lines.

Chipon C, Riffo P, Ojeda L, Salas M, Burgos R, Ehrenfeld P Int J Mol Sci. 2024; 25(21).

PMID: 39519155 PMC: 11546251. DOI: 10.3390/ijms252111601.


Investigation of small molecules disrupting dengue virus assembly by inhibiting capsid protein and blocking RNA encapsulation.

Panday H, Jha A, Dwivedi V Mol Divers. 2024; .

PMID: 39304568 DOI: 10.1007/s11030-024-10980-z.


and Its Pinostrobin for Atopic Dermatitis: Dual 5-Lipoxygenase and Cyclooxygenase-2 Inhibitor and Its Mechanistic Study through Steady-State Kinetics and Molecular Modeling.

Liana D, Eurtivong C, Phanumartwiwath A Antioxidants (Basel). 2024; 13(1).

PMID: 38247498 PMC: 10812521. DOI: 10.3390/antiox13010074.


Nordihydroguaiaretic Acid Affects Undifferentiated and Differentiated Neuroblastoma Cells Differently through Mechanisms that Impact on Cell Viability.

Ferrera P, De la Fuente-Munoz C, Arias C CNS Neurol Disord Drug Targets. 2023; 23(9):1167-1175.

PMID: 38151851 DOI: 10.2174/0118715273268471231013135114.


References
1.
Satoh T, McKercher S, Lipton S . Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med. 2013; 65:645-657. PMC: 3859717. DOI: 10.1016/j.freeradbiomed.2013.07.022. View

2.
Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

3.
Cuadrado A, Manda G, Hassan A, Alcaraz M, Barbas C, Daiber A . Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. 2018; 70(2):348-383. DOI: 10.1124/pr.117.014753. View

4.
Moss M, Varvel N, Nichols M, Reed D, Rosenberry T . Nordihydroguaiaretic acid does not disaggregate beta-amyloid(1-40) protofibrils but does inhibit growth arising from direct protofibril association. Mol Pharmacol. 2004; 66(3):592-600. DOI: 10.1124/mol.66.3.. View

5.
Jeon S, Ji K, You H, Kim J, Jou I, Joe E . Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes. Biochem Biophys Res Commun. 2005; 328(2):595-600. DOI: 10.1016/j.bbrc.2005.01.025. View